Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM37GWL)

• Drug Name: Benzamidine Drug Info
• Synonyms: benzamidine; Benzimidamide; Benzenecarboximidamide; 618-39-3; Phenylamidine; UNII-KUE3ZY3J1F; NSC 243704; CCRIS 2952; Benzamidine (Protonated); EINECS 210-546-3; KUE3ZY3J1F; CHEMBL20936; CHEBI:41033; PXXJHWLDUBFPOL-UHFFFAOYSA-N; BDN; 1oss; 2ast; 1bra; Benzenecarboxamidine; 1v2m; 1v2j; 1h4w; 1ce5; 1c5o; 2j9n; 1f5k; 1c5p; 1v2v; 1v2s; 1v2l; 1c5z; 1v2u; AC1L1DFX; Lopac-B-6506; ACMC-1B9LG; SCHEMBL9207; Lopac0_000203; MLS001066369; GTPL7566; AC1Q1U98; DTXSID8045012; 1670-14-0 (hydrochloride); ZINC36634; CTK2F5055; 1w80; 1j16; 1j15; MolPort-000-001-395

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 2332
  ChEBI ID: CHEMBL41033
  CAS Number: CAS 618-39-3
  TTD Drug ID: DM37GWL

Molecule-Related Drug Atlas

Drug(s) Targeting Urokinase-type plasminogen activator (PLAU)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pro-urokinase	DMGKT2L	Thrombin deficiency	3B14.Z	Approved	[4]
Urokinase	DM0GOUD	Myocardial infarction	BA41-BA43	Approved	[5]
PAI-1	DMY2AEF	N. A.	N. A.	Phase 4	[6]
Amediplase	DM4FPM3	Myocardial infarction	BA41-BA43	Phase 3	[7]
Upamostat	DMFZULI	Breast cancer	2C60-2C65	Phase 2	[8]
Saruplase	DM1M0PR	Thrombosis	DB61-GB90	Phase 2	[9]
HTU-PA	DMNHE43	Cerebrovascular ischaemia	8B1Z	Phase 1/2	[10]
PMID18163548C4	DMHPME3	Myocardial ischemia	BA6Z	Clinical trial	[11]
UK-356202	DMSRK2A	Myocardial hypertrophy	BC45	Clinical trial	[12]
PAI-2	DMRSMW8	N. A.	N. A.	Discontinued in Phase 2	[13]

Drug(s) Targeting Cationic trypsinogen (PRSS1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bortezomib	DMNO38U	Leukemia		Approved	[14]
MELAGATRAN	DM4W8RE	N. A.	N. A.	Phase 3	[15]
Ulinastatin	DMIQCFG	Premature labour	JB00	Phase 3	[16]
Alpha-1 antitrypsin	DM5EFXZ	Coagulation defect	3B10.0	Phase 2	[17]
Dermolastin	DM6WSU2	Atopic dermatitis	EA80	Discontinued in Phase 2	[18]
RWJ-56423	DM6BIHE	Asthma	CA23	Discontinued in Phase 1	[19]
Patamostat	DM6HBQJ	Hypotension	BA20-BA21	Terminated	[17]
BMY-44621	DM8R3N0	N. A.	N. A.	Terminated	[20]
Grassystatin a	DM1PWX2	Discovery agent	N.A.	Investigative	[21]
2-(2-Hydroxy-phenyl)-1H-indole-5-carboxamidine	DM3UMYD	Discovery agent	N.A.	Investigative	[22]

Drug(s) Targeting Suppressor of tumorigenicity 14 protein (ST14)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
US8569313, Inhibitor 18	DMXTCGM	N. A.	N. A.	Patented	[23]
US8569313, Inhibitor 14	DMZV6YT	N. A.	N. A.	Patented	[23]
US8569313, Inhibitor 19	DMLXG43	N. A.	N. A.	Patented	[23]
US8569313, Inhibitor 15	DMTMG02	N. A.	N. A.	Patented	[23]
PMID23849879C3	DMUW3MT	Discovery agent	N.A.	Investigative	[24]
PMID25489658C4d	DMWZJT0	Discovery agent	N.A.	Investigative	[25]
2-nas-phe(3-am)-4-(2-guanidinoethyl)piperidine	DMFXKN1	Discovery agent	N.A.	Investigative	[26]
Inhibitor 1 [Colombo et al., 2012]	DMUQHMP	Discovery agent	N.A.	Investigative	[27]
3-tapap	DMKSUV9	Discovery agent	N.A.	Investigative	[26]

Drug(s) Targeting Kallikrein-6 (KLK6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID24900446C5	DMZ5P2K	Discovery agent	N.A.	Investigative	[28]

Drug(s) Affected By Proto-oncogene tyrosine-protein kinase Src (SRC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bosutinib	DMTI8YE	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[29]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[30]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[31]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[32]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[33]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[34]
Plicamycin	DM7C8YV	Hypercalcaemia	5B91.0	Approved	[35]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[36]
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[36]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[37]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cationic trypsinogen (PRSS1)	TT2WR1T	TRY1_HUMAN	Inhibitor	[2]
Kallikrein-6 (KLK6)	TTLPF4X	KLK6_HUMAN	Inhibitor	[2]
Suppressor of tumorigenicity 14 protein (ST14)	TTPRO7W	ST14_HUMAN	Inhibitor	[2]
Urokinase-type plasminogen activator (PLAU)	TTGY7WI	UROK_HUMAN	Inhibitor	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Proto-oncogene tyrosine-protein kinase Src (SRC)	OTETYX40	SRC_HUMAN	Gene/Protein Processing	[3]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7566).
• [2] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [3] Benzamides and benzamidines as specific inhibitors of epidermal growth factor receptor and v-Src protein tyrosine kinases. Bioorg Med Chem. 2004 Jul 1;12(13):3529-42. doi: 10.1016/j.bmc.2004.04.030.
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2393).
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [6] Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst. 1995 May 17;87(10):751-6.
• [7] Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
• [8] Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer. Br J Cancer. 2013 Mar 5;108(4):766-70.
• [9] Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single-chain urokinase-type plasminogen activator, in patients with acute myocardial infarction. Thromb Haemost. 1994 Nov;72(5):740-4.
• [10] Characterization of the dexamethasone-induced inhibitor of plasminogen activator in HTC hepatoma cells. J Biol Chem. 1986 Mar 25;261(9):4352-7.
• [11] Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator. J Med Chem. 2008 Jan 24;51(2):183-6.
• [12] Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 3: 1-isoquinolinylguanidines. Bioorg Med Chem Lett. 2004 Jun 21;14(12):3227-30.
• [13] Topological localization of plasminogen activator inhibitor type 2. Cytometry. 2000 May 1;40(1):32-41.
• [14] Characterization of a class of peptide boronates with neutral P1 side chains as highly selective inhibitors of thrombin. J Med Chem. 1995 Apr 28;38(9):1511-22.
• [15] Orally active thrombin inhibitors. Part 1: optimization of the P1-moiety. Bioorg Med Chem Lett. 2006 May 15;16(10):2641-7.
• [16] Intravenous administration of ulinastatin (human urinary trypsin inhibitor) in severe sepsis: a multicenter randomized controlled study. Intensive Care Med. 2014 Jun;40(6):830-8.
• [17] US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT.
• [18] Arriva-ProMetic recombinant alpha 1-antitrypsin (rAAT) moves into the clinic for dermatology applications. ProMetic Life Sciences. 2009.
• [19] Inhibitors of serine proteases as potential therapeutic agents: the road from thrombin to tryptase to cathepsin G. J Med Chem. 2004 Feb 12;47(4):769-87.
• [20] Design and synthesis of conformationally constrained arginal thrombin inhibitors, Bioorg. Med. Chem. Lett. 7(17):2205-2210 (1997).
• [21] Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation. J Med Chem. 2009 Sep 24;52(18):5732-47.
• [22] Development of serine protease inhibitors displaying a multicentered short (<2.3 A) hydrogen bond binding mode: inhibitors of urokinase-type plasmi... J Med Chem. 2001 Aug 16;44(17):2753-71.
• [23] Meta-substituted phenyl sulfonyl amides of secondary amino acid amides, the production thereof, and use thereof as matriptase inhibitors. US8569313.
• [24] 1,2,4-Triazole derivatives as transient inactivators of kallikreins involved in skin diseases. Bioorg Med Chem Lett. 2013 Aug 15;23(16):4547-51.
• [25] Toward the first class of suicide inhibitors of kallikreins involved in skin diseases. J Med Chem. 2015 Jan 22;58(2):598-612.
• [26] Secondary amides of sulfonylated 3-amidinophenylalanine. New potent and selective inhibitors of matriptase. J Med Chem. 2006 Jul 13;49(14):4116-26.
• [27] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2418).
• [28] Virtual Screening and X-ray Crystallography for Human Kallikrein 6 Inhibitors with an Amidinothiophene P1 Group. ACS Med Chem Lett. 2012 Jan 11;3(2):159-64.
• [29] SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling. Cancer Res. 2006 Feb 15;66(4):2279-86. doi: 10.1158/0008-5472.CAN-05-2057.
• [30] Selective activation of Src family kinases and JNK by low levels of chromium(VI). Toxicol Appl Pharmacol. 2003 Aug 1;190(3):214-23. doi: 10.1016/s0041-008x(03)00188-1.
• [31] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [32] Quercetin exerts anti-melanoma activities and inhibits STAT3 signaling. Biochem Pharmacol. 2014 Feb 1;87(3):424-34. doi: 10.1016/j.bcp.2013.11.008. Epub 2013 Nov 23.
• [33] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [34] Dehydroepiandrosterone Activation of G-protein-coupled Estrogen Receptor Rapidly Stimulates MicroRNA-21 Transcription in Human Hepatocellular Carcinoma Cells. J Biol Chem. 2015 Jun 19;290(25):15799-15811. doi: 10.1074/jbc.M115.641167. Epub 2015 May 11.
• [35] Mithramycin inhibits human epithelial carcinoma cell proliferation and migration involving downregulation of Eps8 expression. Chem Biol Interact. 2010 Jan 5;183(1):181-6. doi: 10.1016/j.cbi.2009.09.018.
• [36] The differential cancer growth associated with anaesthetics in a cancer xenograft model of mice: mechanisms and implications of postoperative cancer recurrence. Cell Biol Toxicol. 2023 Aug;39(4):1561-1575. doi: 10.1007/s10565-022-09747-9. Epub 2022 Aug 12.
• [37] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.